following an abbreviated submission:
rufinamide (Inovelon®) is accepted for restricted use within NHSScotland.
Indication under review: as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to ≤4 years.
SMC restriction: restricted to use in patients who have failed treatment with or are intolerant of other antiepileptic drugs.
Rufinamide (Inovelon®) has previously been accepted for restricted use in adults and children aged >4 years. The licence has been extended to include children aged 1 year to ≤4 years.
To read more Press Release articles, click here.